Clarify, Datavant team up to securely connect first-party and real-world data

By Nick Taylor

- Last updated on GMT

(pagadesign/iStock via Getty Images Plus)
(pagadesign/iStock via Getty Images Plus)

Related tags Datavant Patient centricity patient engagement Patient recruitment Clinical trials Data management

The companies will work together to help clients connect information sources, giving stakeholders a better overview of the clinical patient experience.

Clarify Health has expanded its strategic partnership with Datavant to help life sciences companies connect first-party and real-world data.

Linking healthcare data at the patient level gives clinical researchers and commercial teams a fuller view of the longitudinal patient journey, thereby supporting the identification of recruitment and adoption opportunities for patients. However, life sciences companies face challenges when trying to realize the benefits.

Todd Gottula, co-founder and president, Clarify

High-scale data management has become even more complex as the demand for more and more patient-level insights has accelerated the demand on digital transformation in the life sciences industry. With this rapid evolution, leaders must keep data security and patient privacy top of mind​,” said Todd Gottula, co-founder and president of Clarify.

Clarify has responded to the opportunities and challenges by partnering with Datavant, the developer of a HIPAA-compliant, privacy-preserving tokenization technology. By working with Datavant, Clarify aims to guard protected health information while connecting life sciences companies’ first-party data to its Atlas Platform.

The Atlas Platform maps over 4b care journeys across more than 300m unique individuals. Gottula sees value in helping life sciences companies to integrate their data with the real-world data in Clarify’s Atlas Platform.

Clarify enables [clinical researchers] to measure long-term effectiveness and outcomes of new therapies in a higher fidelity way because these teams are able to leverage critical private data with what Clarify has sourced in the market. Similarly, this linked data empowers commercial teams to better understand patterns in treatment sequencing, therapy adoption, and patient access​,” said the Clarify president.

News of the Datavant partnership comes four months after Clarify disclosed a $150m USD Series D financing round. The funding positions Clarify to build on its progress to date, which includes the development of a tool to enable life sciences researchers to explore treatment patterns across years of longitudinal data and characterize patient cohorts across hundreds of medical, social, and genomic factors.

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us


View more